Tg Therapeutics, Inc.

This study will follow 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI, a medication given by infusion. Researchers want to see how well the drug works in everyday life and track any side effects. Participants must not have received BRIUMVI before and can…

This study tests a modified dosing schedule of ublituximab, a drug that targets certain immune cells, in 800 people with relapsing multiple sclerosis (MS). The goal is to see if the new regimen reduces brain lesions better than current approaches. Participants include those new t…

This study tests if a shot (subcutaneous) of the drug ublituximab works as well as the standard IV version for people with relapsing multiple sclerosis. About 360 adults with MS will receive either the shot or the IV, and researchers will measure drug levels in the blood and moni…

This is an early-stage study testing the safety and initial effects of a new CAR T-cell therapy called azercabtagene zapreleucel for people with B-cell mediated autoimmune disorders like progressive multiple sclerosis. The study will enroll 32 participants to find the right dose …

This study observes pregnant women with multiple sclerosis to see if taking BRIUMVI affects the baby's health. It compares birth defect rates between women who used BRIUMVI during pregnancy and those who did not. About 728 participants will provide data to help doctors understand…

This study looks at how much of the multiple sclerosis drug BRIUMVI passes into breast milk. About 16 women with relapsing MS who are already taking BRIUMVI and choose to breastfeed will provide milk samples. The goal is to measure drug levels, not to treat or cure the disease.